C12N 5/0648
Splenocytes
Official title: {Splenocytes}
C12N5/0648 (Splenocytes) appears on 23 US grants and 53 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 53
- Assignees
- 34
- Inventors
- 108
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 4 |
| 2004 | 0 | 2 |
| 2005 | 0 | 3 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 2 |
| 2011 | 2 | 0 |
| 2012 | 0 | 4 |
| 2013 | 0 | 2 |
| 2014 | 0 | 3 |
| 2015 | 0 | 2 |
| 2016 | 1 | 2 |
| 2017 | 2 | 3 |
| 2018 | 2 | 7 |
| 2019 | 1 | 0 |
| 2020 | 4 | 3 |
| 2021 | 4 | 1 |
| 2022 | 0 | 4 |
| 2023 | 2 | 0 |
| 2024 | 0 | 3 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified anti-third party central memory T cells and use of same in immunotherapy30 Dec 2025US 12,508,307 B2Yeda Research and Development Co. Ltd.
- Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells25 Feb 2025US 12,234,480 B2Albert-Ludwigs-Universität Freiburg
- Genetically modified anti-third party central memory T cells and use of same in immunotherapy19 Dec 2023US 11,844,827 B2Yeda Research and Development Co. Ltd.
- Delivery of biomolecules to PBMCs to modify an immune response4 Jul 2023US 11,692,168 B2SQZ Biotechnologies Company
- Genetically modified anti-third party central memory T cells and use of same in immunotherapy23 Nov 2021US 11,179,448 B2Yeda Research and Development Co. Ltd.
- Method for producing immortalized cell1 Jan 2026US 2026/0002127 A1Kitayama Labes Co., Ltd.
- Compositions and methods for antigen-specific tolerance25 Dec 2025US 2025/0387461 A1Myelin Repair Foundation, Inc.
- Methods for selectively reducing immunogenicity in a transplant13 Mar 2025US 2025/0084370 A1Transimmune AG
- Delivery of biomolecules to pbmcs to modify an immune response11 Jul 2024US 2024/0228956 A9SQZ Biotechnologies Company
- Genetically modified anti-third party central memory t cells and use of same in immunotherapy9 May 2024US 2024/0148845 A1Yeda Research and Development Co. Ltd.
Most cited
By later US patents
- Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications38US 6,165,785 AShriners Hospitals for Children · 2000
- Method to increase the density of antigen on antigen presenting cells30US 5,831,068 ADuke University · 1998
- Methods of organ regeneration using Hox 11-expressing pluripotent cells27US 7,582,313 B2The General Hospital Corporation · 2009
- Methods of organ regeneration using Hox11-expressing pluripotent cells18US 8,021,693 B2The General Hospital Corporation · 2011
- Hox11+, CD45− cells and methods of organ regeneration using the same8US 8,017,392 B2The General Hospital Corporation · 2011